SCHEMBL19306200

SCHEMBL19306200

O=C(Nc1ccccn1)OCCO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
PKM P14618 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
PIM1 P11309 1/20 0.49
ADORA2A P29274 1/20 0.49
ADORA2B P29275 1/20 0.49
ADORA1 P30542 1/20 0.49
FLT3 P36888 1/20 0.49
PIM3 Q86V86 1/20 0.49
AURKB Q96GD4 1/20 0.49
TP53 P04637 1/20 0.47
LMNA P02545 2/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23012307 0.87 GAA (0.61) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL30048800 0.83 GAA (0.53) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL18640790 0.83 GAA (0.59) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL1921112 0.83 SMN1; SMN2 (0.59) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL29655094 0.82 NPC1 (0.60) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL6179239 0.82 NPC1 (0.60) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL29814844 0.82 MEN1 (0.62) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL28361102 0.82 GAA (0.51) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL29814911 0.82 SMN1; SMN2 (0.58) GAANPC1RAB9APKMSMN1; SMN2
SCHEMBL8588883 0.81 ALOX12 (0.60) GAANPC1RAB9APKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 EP disclosed
CN-108883099-B Thiazolidinone compounds and use thereof 石全 2021-09-28 CN disclosed
US-10544113-B2 Thiazolidinone compounds and use thereof NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2020-01-28 US disclosed
EP-3426246-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF National Health Research Institutes (TW) 2019-01-16 EP disclosed
CN-108883099-A THIAZOLIDINONE COMPOUNDS AND USE THEREOF 石全 2018-11-23 CN disclosed
WO-2017155910-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2017-09-14 WO disclosed
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544113-B2 Thiazolidinone compounds and use thereof OPRL1, OPRD1, OPRK1 GAA 1589/4885NPC1 730/4885RAB9A 2807/4885
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF OPRL1, OPRD1, OPRK1 GAA 1589/4885NPC1 730/4885RAB9A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.